TITLE OF STUDY |
PHASE |
INDICATION |
|
A 12-week randomized, double-blind, placebo-controlled parallel-group, fixed-dosage study to evaluate the efficacy and safety of Armodafinil (50, 150, and 250 mg/day) As treatment for patients with excessive sleepiness assoicated with mild or moderate closed traumatic brain injury |
III |
Sleep Disorder |
Closed |
An evaluation of lung function and symptoms in patients with Chronic Obstructive Pulmonary Disease (COPD) on long-acting bronchodilator monotherapy <years |
IV |
COPD |
Closed |
A prospective, multinational, multicenter, double-blind, randomized, active-controlled trial to compare the effects of Lotrel (amlodipine / benazepril) to benazepril and hydrochlorothiazide combined on the reduction of cardiovascular morbidity and mortality in patients with high risk hypertension |
III |
Hypertension |
|
| A Phase IIIB, 12-Month, Double-blind, Double-dummy, Randomised, Parallel-group, Multicentre Exacerbation Study of SYMBICORT® pMDI 160/4.5 µg x 2 Actuations Twice-daily and 80/4.5 µg x 2 Actuations Twice-daily Compared to Formoterol TBH 4.5 µg x 2 Inhalations Twice-daily in COPD Subjects |
III |
COPD |
Closed |
A multinational, randomized, double-blind, placebo-controlled, forced titration, 2 x 2 factorial design study of the efficacy and safety of long term administration of nateglinide and valsartan in the prevention of diabetes and cardiovascular outcomes in subjects with impaired glucose tolerance (IGT) |
III |
Type II Diabetes Mellitus |
|
A multicenter, randomized, double blind, parallel design trial to evaluate the blood pressure lowering efficacy comparing moderate versus aggressive treatment regimen of Exforge in patients uncontrolled on ARB monotherapy |
III |
Hypertension |
Closed |
A 12-week treatment, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of once daily indacaterol in patients with chronic obstructive pulmonary disease |
II |
COPD |
Closed |
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) Following Hospitalization |
III |
|
Closed |
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Armodafinil Treatment (150mg) in Imporving Clinical Condition Late in the Shift and in Improving Functional and Patient-Reported Outcomes in Adult Patients With Excessive Sleepiness Associated With Shift Work Disorder |
III |
|
|
| A 12-week, randomized, double-blind, placebo-controlled, parallel group, multinational, phase IIb dose range finding study to evaluate the efficacy and safety of AZD9668 administered orally at 3 dose levels to patients with Chronic Obstructive Pulmonary Disease (COPD) on treatment with tiotropium |
III |
|
Closed |
Efficacy and safety of inhaled human insulin (Exubera) compared with subcutaneous human insulin in the therapy of adult subjects with Type 1 or Type II Diabetes Mellitus and chronic obstructive pulmonary disease: A one year , multicenter, randomized, outpatient, open-label, parallel group comparative trial |
II |
COPD/DM |
Closed |
A SAFETY AND EFFICACY TRIAL EVALUATING THE USE OF APIXABAN FOR THE EXTENDED TREATMENT OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM |
III |
Deep Vein Thrombosis |
Closed |
A Multicenter, Double-blind, Randomized, Active Controlled Study to Compare the Effect of 52 Weeks Treatment with Vildagliptin 50 mg bid to Pioglitazone 30 mg Daily as Add-On Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy |
III |
Type II Diabetes Mellitus |
Closed |
|
A 80-week extension to a mulitcenter, randomized, double-blind, active controlled study to compare the effect of 24 weeks treatment with LAF 237 50 mg bid to rosiglitazone 8 mg qd in drug naïve patients with type 2 diabetes |
III |
Type II Diabetes Mellitus |
Closed |
|
A multi-center, randomized, open-label, active controlled, parallel arm study to compare the efficacy of 12 weeks of treatment with Vildagliptin 100 mg, qd to thiazolidinedione (TZD) as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin in a community-based practice setting |
III |
Type II Diabetes Mellitus |
Closed |
A Randomized, Double-Blind, Parallel Group, 52-week Study to Compare the Effect of the Fluticasone Propionate/Salmeterol DISKUS™ Combination Product 250/50mcg BID with Salmeterol DISKUS 50mcg BID on the Annual Rate of Moderate/Severe Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD) |
IV |
COPD |
|
A randomized, parallel group, double-blind, multi-center study comparing the efficacy and safety of Avandament and Metformin after 80 weeks of treatment |
III |
Type II Diabetes Mellitus |
|
A 12/6 month, double-dummy, randomized, parallel group, multicenter efficacy and safety study of SYMBICORT pMDI 2 x 160/4.5 mcg and 80/4/5 mcg bid compared to Formoterol TBH, Budesonide pMDI (and the combination) and placebo in COPD patients |
III |
COPD |
|
|
A multi-site, cross-sectional, non-treatment, prospective trial to collect bio-fluids and neuropsychiatric data from cognitively normal elderly subjects |
Method Trial |
Psychiatric |
Closed |
|
A 26-week treatment, multicenter, randomized, double-blind, double dummy, placebo-controlled, adaptive, seamless, parallel-group study to assess the efficacy, safety and tolerability of two doses of indacaterol (selected from 75, 150, 300, & 600 ug o.d.) in patients with chronic obstructive pulmonary disease using blinded formoterol (12 ug b.i.d) and open label tiotropium (18 ug o.d.) as active controls |
II / III |
COPD |
Closed |
|
Incidence of airway obstruction consistent with chronic obstructive pulmonary disease (COPD) in subjects with a history of cigarette smoking and symptoms of chronic bronchitis in a primary care setting |
IV |
COPD |
Closed |
A 28-week extension to a multicenter, double-blind, randomized, parallel-group study to compare the effect of 24 weeks treatment with LAF237 (50 mg qd or bid) to placebo as add-on therapy to pioglitazone 45 mg qd in patients with type 2 diabetes inadequately controlled with thiazolidinedione monotherapy |
III |
Type II Diabetes Mellitus |
|
A Multicenter, Double-blind, Randomized, Active Controlled Study to Compare the Effect of 52 Weeks Treatment with Vildagliptin 50 mg bid to Pioglitazone 30 mg Daily as Add-On Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy |
III |
Type II Diabetes Mellitus |
Closed |
A 80-week extension to a mulitcenter, randomized, double-blind, active controlled study to compare the effect of 24 weeks treatment with LAF237 50 mg bid to rosiglitazone 8 mg qd in drug naïve patients with type 2 diabetes |
III |
Type II Diabetes Mellitus |
|
L-TAP2: Lipid Treatment Assessment Project 2 |
Observational Survey |
Dislipidemia |
|
An 8-week randomized, double-blind, parallel group, multi-center, placebo and active controlled dose escalation study to evaluate the efficacy and safety of aliskiren (150 mg and 300mg) administered alone and in combination with valsartan (160 mg and 320 mg) in patients with hypertension |
III |
Hypertension |
|
A 13-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group trial of lumiracoxib (COX189) 100 mg o.d. in patients with primary hip osteoarthritis using celecoxib (200 mg o.d.) as a positive control |
III |
Osteoarthritis (Hip) |
|
A multi-center, randomized, double-blind, study to compare the effect of 24 weeks treatment with LAF 237 (50 mg qd, 50 mg bid or 100 mg qd) or placebo in drug naïve patients with type 2 diabetes |
|
|
|
A multi-center, randomized, double-blind study to compare the effects of 24 weeks treatment with LAF 237 (50 mg qd, 50 mg bid or 100 mg qd) to placebo in drug naïve patients with type 2 diabetes |
|
|
|
A 12-week, parallel-group, double blind, randomized, Placebo-controlled, multi-center, dose ranging study to Evaluate the efficacy, safety, and tolerability of GW823093 (2.5 mg, 7.5 mg, 15 mg, 30 mg, and 45 mg) administered orally, once daily, as monotherapy in subjects with type II Diabetes Mellitus |
|
|
|
A 12 week, randomized, double-blind, placebo controlled, parallel group study to evaluate the efficacy and safety of CEP-10953 (150 mg) as treatment for adults with excessive sleepiness associated with chronic shift work sleep disorder |
|
|
|
A 12 week randomized, double-blind, placebo- controlled, parallel group study to evaluate the safety and efficacy of CEP-10953 (150 mg/day) as treatment for adults with residual excessive sleepiness associated with obstructive sleep apnea/ Hypopnea syndrome |
|
|
|
A 12 month, open label, flexible dosage (100 to 250 mg/day) extension study of the safety and efficacy of CEP-10953 in the treatment of patients with excessive sleepiness associated with narcolepsy obstructive sleep apnea/hypopnea syndrome or chronic shift work sleep disorder |
|
|
|
A randomized, double blind, placebo controlled parallel group study of the efficacy and multiple dose plasma concentration time profiles of Armodafinil (150, 200, and 250 mg) and Provigil (200 mg) in patients with chronic shift work sleep disorder |
|
|
|
A randomized, double-blind study to compare the durability of glucose lowering and preservation of pancreatic beta-cell function of Rosiglitazone Monotherapy compared to Metformin or Glyburide/ Glibenclamide in patients with drug-naïve, recently Diagnosed type 2 diabetes mellitus |
|
|
|
A 12 month, randomized, open label, multicenter, study to assess the long term safety of aliskiren 150 mg alone and 300 mg alone or with the optional addition of hydrochlorothiazide (12.5 mg or 25 mg) in patients with essential hypertension |
|
|
|
A 13-week, multi-center, randomized, double-blind, Double-dummy, placebo-controlled, parallel trial of 2 Different dose regimens of lumiracoxib (100 mg od And 200 mg od initial dose for two weeks followed by 100 mg od) in patients with primary knee osteoarthritis, using celecoxib (200 mg od) as a comparator |
|
|
|
A multi-center, randomized, parallel-group study to compare the effect of 24 weeks treatment with LAF 237 (50 mg qd or bid) to placebo as add on therapy in patients with type 2 diabetes inadequately controlled with glimerpiride monotherapy |
|
|
|
